The identified GR/P63 interplay in keratinocytes opens the possibility of novel therapeutic strategies for cutaneous disorders where the combined use of lower GC doses together with P63 inhibitors may provide clinical benefit. This evidence concerns the gene NR3C1 and skin disorder.